Anti–glomerular basement membrane disease with rapidly progressive glomerulonephritis and hemorrhagic alveolitis in pediatric patients (reviev of literature)
https://doi.org/10.36485/1561-6274-2022-26-3-9-18
Abstract
The article is devoted to controversial issues of autoimmune small vessel vasculitis with kidney and lung damage. Modern data on the features of pathogenesis, clinical manifestation, treatment, outcome, and prognosis of the disease with AT to GBM have presented: an idiopathic disease with AT of class IgG (IgG1 and IgG3) against non-collagen domain-1 (NC1) α3-chain of
collagen type IV GBM (Goodpasture autoantigen); with the simultaneous increase in AT to GBM and ANCA; "de novo" diseases with AT to the α5(IV) and α3(IV) chains of GBM type IV collagen in renal graft with Alport syndrome in pediatric patients.
About the Authors
N. D. Savenkova
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Nadezhda D. Savenkova, Professor, Doctor of Medical Sciences, Head of the Department
Department of Faculty Pediatrics
194100
Litovskaya str., 2
Saint-Petersburg
phone: (812) 4165286
K. A. Papayan
St. Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Karina A. Papayan, Associate Professor, Candidate of Medical Sciences
Department of Faculty Pediatrics
194100
Litovskaya str., 2
Saint-Petersburg
phone: (812) 4165286
References
1. Butani L. Rapidly Progressive Glomerulonephritis. Adolescents with Chronic Kidney Disease. From Diagnosis to End-Stage Disease. Eds: Maha N. Haddad, Erica Winnicki, Stephanie Nguyen. Springer Nature Switzerland AG 2019; 93–106. doi: 10.1007/978-3-319-97220-6
2. Bagga A., Shina M. Rapidly Progressive Glomerulonephritis. Еds: Denis F. Geary and Franz Schaefer. Pediatric Kidney Disease. Springer-Verlag, Berlin-Heidelberg. 2016. URL: https://link.springer.com/chapter/10.1007/978-3-662-52972-0_22?error=cookies_not_supported&code=4be1e51c-d425-4cb1-8282-340ea1fee75c
3. Bayat A., Kamperis K., Herlin T. Characteristics and out-come of Goodpasture’s disease in children. Clin Rheumatol 2012; 31 (12): 1745–1751. doi: 10.1007/s10067-012-2062-9
4. Dorval G., Guérin S., Berteloot L., S Krid, R. Salomon R., Galmiche-Rolland L., Boyer O. Syndrome de Goodpasture et maladie des anticorps anti-membrane basale chez l’enfant: revue de la literature Archives de Pediatrie 2017;24 (10):101–91028. doi: 10.1016/j.arcped.2017.07.013
5. Greco A., Rizzo M. I., De Virgilio A., Gallo A., Fusconi M., Pagliuca G., et al. Goodpasture’s syndrome: a clinical update. Autoimmun Rev 2015;14 (3): 246–253. doi: 10.1016/j.autrev.2014.11.006
6. McAdoo S. P. and Pusey C. D. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol 2017;12 (7): 1162–1172. doi: 10.2215/CJN.01380217
7. Hellmark T., Segelmark M. Diagnosis and classification of Goodpasture's disease (anti-GBM). J Autoimmun 2014; 48–49:108–112. doi: 10.1016/j.jaut.2014.01.024
8. Jenette J. C. Overview of the 2012 revized International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Clin Exp Nephrol 2013; 17:60–606. doi:10.1007/s10157-013-0869-6
9. Iorember F., Vehaskari V. M. Rapidly Progressive Glomerulonephritis and vasculitis. In Clinical Pediatric Nephrology. Eds. K. K. Kher, H. W. Schnaper, L. A. Greenbaum. Third Edition CRC Press Taylor & Francis Group. 2017; 419–434. International Standard Book Number-13: 978-1-4822-1462-8
10. Fisher M., Pusey C. D., Vaughan R. W., Rees A. J. (1997) Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1genes. Kidney Int 1997; 51 (1): 222–229. doi: 10.1038/ki.1997.27
11. Licht C., Kirschfink M. The Role of Complement in Disease. Pediatric Kidney Disease. Denis F. Geary and Franz Schaefer (eds.). Springer-Verlag Berlin Heidelberg 2016. doi: 10.1007/978-3-662-52972-0_23
12. Ma R., Cui Z., Liao Y. H., Zhao M.-H. Complement activation contributes to the injury and outcome of kidney in human antiglomerular basement membrane disease. J Clin Immunol 2013; 33: 172–178. doi: 10.1007/s10875-012-9772-2
13. Ma R., Zhao H.-Z., Hu S.-Yi, Jia H.-Y., Yang R., Xin Z. X., Ao J., Liu G., Liao Y.-H., Zhao M.-H. The Alternative Pathway of Complement Activation May Be Involved in the Renal Damage of Human Anti-Glomerular Basement Membrane Disease. PLoS One 2014; 9 (3): e91250. doi: 10.1371/journal.pone.0091250
14. Flynn J. O., Kotimaa J., Faber-Krol R., Koekkoek K., Klar-Mohamad N., Koudijs A., Jschwaeble W., Stover С., van Kooten C. Properdin binds independent of complement activation in an in vivo model of anti-glomerular basement membrane disease. Kidney Int 2018; doi: 10.1016/j.kint.2018.06.030
15. Şişmanlar-Eyüboğlu T., Aslan A. T., Gezgin-Yıldırım D., Buyan N., Emeksiz S., Kalkan G. What triggered massive hemoptysis in Goodpasture syndrome with isolated pulmonary involvement in a 14-year-old boy? Turk J Pediatr 2019; 61: 611–614. doi: 10.24953/turkjped.2019.04.022
16. Nagano C., Goto Y., Kasahara K., Kuroyanagi Y. Case report: antiglomerular basement membrane antibody disease with normal renal function. BMC Nephrol 2015; 4 (16): 185. doi: 10.1186/s12882-015-0179-1
17. Gittins N., Basu A., Eyre J., Gholkar A., Moghal N. Cerebral vasculitis in a teenager with Goodpasture’s syndrome. Nephrol Dial Transplant 2004; 19 (12): 3168–3171. doi: 10.1093/ndt/gfh448
18. Williams S. R., Phillips C. L., Andreolli S. P., Nailesseu C. A 25-year experience anti-glomerular basement membrane disease. Pediatr Nephrol 2011; 26:85–91. doi: 10.1007/s00467-010-1663-2
19. Menzi C. P., Bucher B. S., Bianchetti M. G., Ardissino G., Simonetti G. D. Management and outcomes of childhood Goodpasture's disease. Pediatr Res 2018; 83 (4): 813–817. doi: 10.1038/pr.2017.315
20. Canney M., Little M. A. ANCA in anti-GBM disease: moving beyond a one-dimensional clinical phenotype. Kidney Int 2017; 92 (3): 544–546. doi: 10.1016/j.kint.2017.03.014
21. Yuan J., Chen M., Zhao V.-H. Complement in antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Nephrol 2013; 17: 642– 645. doi: 10.1007/s10157-012-0700-9
22. Balderia P. G., Jonathan N., Jefferson A. Characteristics and Outcomes of Patients with Anti-Glomerular Basement Membrane Antibody Disease and Anti-Neutrophil Cytoplasmic Antibodies. Curr Rheumatol Rev 2019; 15 (3): 224–228. doi: 10.2174/1573397114666180516131240
23. McAdoo S. P., Tanna A., Hrušková Z., Holm L., Weiner M., Arulkumaran N., Kang A., Satrapová V., Levy J., Ohlsson S., Tesar V., Segelmark M., Pusey C. D. Patients doubleseropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients. Kidney Int 2017; 92 (3): 693–702. doi: 10.1016/j.kint.2017.03.014
24. Rheault M. N. and Kashtan C. E. Alport Syndrome and Thin Basement Membrane Nephropathy. Pediatric Kidney Disease. Denis F. Geary and Franz Schaefer (eds.). Springer-Verlag Berlin Heidelberg 2016. doi: 10.1007/978-3-662-52972-0_18
25. Kashtan C. E. Renal transplantation in patients with Alport syndrome: patient selection, outcomes, and donor evaluation. Int J Nephrol Renovasc Dis 2018 Oct 16;11:267–270. doi: 10.2147/IJNRD.S150539
26. Lookwood C. M., Pinching A. J., Sweny P., Rees A. J., Pussell B., Uff G., Petters D. K. Plasma- exchange and immunosupression in the treatment of fulminating immuneomplex crescentic nephritis. Lancet 1977; 1: 63–67. doi: 10.1016/s0140-6736(77)91079-0
27. Huart A., Josse A. G., Chauveau D., Korach J. M., Heshmati F., Bauvin E., Cointault O., Kamar N., Ribes D., Pourrat J., Faguer S. Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun 2016; 73: 24–29. doi: 10.1016/j.jaut.2016.05.015
28. Dorval G., Lion M., Guérin S. et al. Immunoadsorption in anti-GBM glomerulonephritis: case report in a child and literature review. Pediatrics 2017; 140 (5) 20161733. doi: 10.1542/peds.2016-1733
29. Guileven L. Treatment of primary systemic necrotizing vasculitides: the role of biotherapies. Clin Exp Nephrol 2013; 17: 627–606. doi:10.1007/s10157-013-0860-2
30. Touzot M., Poisson J., Faguer S., Ribes D., Cohen P., Geffray L., et al. Rituximab in anti-GBM disease: a retrospective study of 8 patients. J Autoimmun 2015; 60:74–79. doi: 10.1016/j.jaut.2015.04.003
31. Chittka D., Lennartz L., Jung B. et al. Erfolgreiche Rituximab therapie des Rezidivs einer Glomerulonephritis assoziiert mit Antikörpern gegen die glomeruläre Basal membran. Internist 2020; 61 (4): 416–423. doi: 10.1007/s00108-020-00773-5
32. Plumb L. A., Oni L., Marks S. D., Tullus K. Anti-Neutrophil Cytoplasmic Antibody (ANCA) –associated vasculitis: an update on renal management. Pediatr Nephrol 2018; 33 (1): 25–39. doi: 10.1007/s00467-016-3559-2
33. Савенкова Н. Д. Стратегия терапии ANCA-ассоциированных васкулитов у детей и подростков / Н. Д. Саенкова // Нефрология. – 2019. – 23 (5): 107–115. URL: https://cyberleninka.ru/article/n/strategiya-terapii-anca-assotsiirovannyh-renalnyh-vaskulitov-u-detey-i-podrostkov?ysclid=l7u41qh9ta92816583 / Savenkova N. D. Strategiya terapii ANCA- associirovanny`x vaskulitov u detej i podrostkov. Nefrologiya (Saint-Petersburg) 2019; 23 (5): 107–115. URL: https://cyberleninka.ru/article/n/strategiya-terapii-anca-assotsiirovannyh-renalnyh-vaskulitov-u-detey-i-podrostkov?ysclid=l7u41qh9ta92816583 (In Russ.)
34. Walters G. Role of therapeutic plasmapheresis in ANCA-associated vasculitis. Pediatr Nephrol 2016; 31: 217–225. doi: 10.1007/s00467-014-3038-6
35. Maliakkal J. G., Hicks M. J., Michael M., Selewski D. T., Twombley K., Rheault M. N., Seamon M., Misurac J. M., Tran C. L., Reyes L., Flynn J. T., Onder A. M., Constantinescu A. R., Singh V., Pan C., Omoloja A., Wu Q., Smoyer W. E., Hidalgo G., Wenderfer S. E. Renal Survival in Children with Glomerulonephritis with Crescents: A Pediatric Nephrology Research Consortium Cohort Study. J Clin Med 2020; 9 (8): 2385. doi: 10.3390/jcm9082385. PMID: 32722612
Review
For citations:
Savenkova N.D., Papayan K.A. Anti–glomerular basement membrane disease with rapidly progressive glomerulonephritis and hemorrhagic alveolitis in pediatric patients (reviev of literature). Nephrology (Saint-Petersburg). 2022;26(3):9-18. (In Russ.) https://doi.org/10.36485/1561-6274-2022-26-3-9-18
Views:
459
Email this article 